Amelia L Sutton1, Edward P Acosta2, Kajal B Larson2, Corenna D Kerstner-Wood2, Alan T Tita3, Joseph R Biggio3. 1. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL. Electronic address: alsutton@uabmc.edu. 2. Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL. 3. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL.
Abstract
OBJECTIVE: Postpartum infections are polymicrobial and typically include Ureaplasma, an intracellular microbe that is treated by macrolides such as azithromycin. The aim of this study was to evaluate the perinatal pharmacokinetics of azithromycin after a single preincision dose before cesarean delivery. STUDY DESIGN:Thirty women who underwent scheduled cesarean delivery were assigned randomly to receive 500 mg of intravenous azithromycin that was initiated 15, 30, or 60 minutes before incision and infused over 1 hour. Serial maternal plasma samples were drawn from the end of infusion up to 8 hours after the infusion. Samples of amniotic fluid, umbilical cord blood, placenta, myometrium, and adipose tissue were collected intraoperatively. Breast milk samples were collected 12-48 hours after the infusion in 8 women who were breastfeeding. Azithromycin was quantified with high performance liquid chromatography separation coupled with tandem mass spectrometry detection. Plasma pharmacokinetic parameters were estimated with the use of noncompartmental analysis and compartmental modeling and simulations. RESULTS: The maximum maternal plasma concentration was reached within 1 hour and exceeded the in vitro minimum inhibitory concentration (MIC50) of 250 ng/mL of Ureaplasma spp in all 30 patients. The concentrations were sustained with a half-life of 6.7 hours. The median concentration of azithromycin in adipose tissue was 102 ng/g, which was below the MIC50. The median concentration in myometrium was 402 ng/g, which exceeded the MIC50. Azithromycin was detectable in both the umbilical cord plasma and amniotic fluid after the single preoperative dose. Azithromycin concentrations in breast milk were high and were sustained up to 48 hours after the single dose. Simulations demonstrated accumulation in breast milk after multiple doses. CONCLUSION: A single dose of azithromycin achieves effective plasma and tissue concentrations and is transported rapidly across the placenta. The tissue concentrations that are achieved in the myometrium exceed the MIC50 for Ureaplasma spp.
RCT Entities:
OBJECTIVE: Postpartum infections are polymicrobial and typically include Ureaplasma, an intracellular microbe that is treated by macrolides such as azithromycin. The aim of this study was to evaluate the perinatal pharmacokinetics of azithromycin after a single preincision dose before cesarean delivery. STUDY DESIGN: Thirty women who underwent scheduled cesarean delivery were assigned randomly to receive 500 mg of intravenous azithromycin that was initiated 15, 30, or 60 minutes before incision and infused over 1 hour. Serial maternal plasma samples were drawn from the end of infusion up to 8 hours after the infusion. Samples of amniotic fluid, umbilical cord blood, placenta, myometrium, and adipose tissue were collected intraoperatively. Breast milk samples were collected 12-48 hours after the infusion in 8 women who were breastfeeding. Azithromycin was quantified with high performance liquid chromatography separation coupled with tandem mass spectrometry detection. Plasma pharmacokinetic parameters were estimated with the use of noncompartmental analysis and compartmental modeling and simulations. RESULTS: The maximum maternal plasma concentration was reached within 1 hour and exceeded the in vitro minimum inhibitory concentration (MIC50) of 250 ng/mL of Ureaplasma spp in all 30 patients. The concentrations were sustained with a half-life of 6.7 hours. The median concentration of azithromycin in adipose tissue was 102 ng/g, which was below the MIC50. The median concentration in myometrium was 402 ng/g, which exceeded the MIC50. Azithromycin was detectable in both the umbilical cord plasma and amniotic fluid after the single preoperative dose. Azithromycin concentrations in breast milk were high and were sustained up to 48 hours after the single dose. Simulations demonstrated accumulation in breast milk after multiple doses. CONCLUSION: A single dose of azithromycin achieves effective plasma and tissue concentrations and is transported rapidly across the placenta. The tissue concentrations that are achieved in the myometrium exceed the MIC50 for Ureaplasma spp.
Authors: Alan T N Tita; John C Hauth; Anne Grimes; John Owen; Alan M Stamm; William W Andrews Journal: Obstet Gynecol Date: 2008-01 Impact factor: 7.661
Authors: Ken B Waites; Robert L Schelonka; Li Xiao; Peta L Grigsby; Miles J Novy Journal: Semin Fetal Neonatal Med Date: 2008-12-23 Impact factor: 3.926
Authors: Maged M Costantine; Mahbubur Rahman; Labib Ghulmiyah; Benjamin D Byers; Monica Longo; Tony Wen; Gary D V Hankins; George R Saade Journal: Am J Obstet Gynecol Date: 2008-09 Impact factor: 8.661
Authors: Alan T N Tita; John Owen; Alan M Stamm; Anne Grimes; John C Hauth; William W Andrews Journal: Am J Obstet Gynecol Date: 2008-09 Impact factor: 8.661
Authors: Hubert O Ballard; Lori A Shook; Philip Bernard; Michael I Anstead; Robert Kuhn; Vicki Whitehead; Deb Grider; Timothy N Crawford; Don Hayes Journal: Pediatr Pulmonol Date: 2010-10-20
Authors: Scott A Walls; Lingkun Kong; Hedda A Leeming; Frank X Placencia; Edwina J Popek; Leonard E Weisman Journal: Pediatr Res Date: 2009-08 Impact factor: 3.756
Authors: Hanna Retallack; Elizabeth Di Lullo; Carolina Arias; Kristeene A Knopp; Matthew T Laurie; Carmen Sandoval-Espinosa; Walter R Mancia Leon; Robert Krencik; Erik M Ullian; Julien Spatazza; Alex A Pollen; Caleigh Mandel-Brehm; Tomasz J Nowakowski; Arnold R Kriegstein; Joseph L DeRisi Journal: Proc Natl Acad Sci U S A Date: 2016-11-29 Impact factor: 11.205
Authors: Ayodeji Sanusi; Yuanfan Ye; Kim Boggess; George Saade; Sherri Longo; Erin Clark; Sean Esplin; Kirsten Cleary; Ron Wapner; Michelle Owens; Sean Blackwell; Jeff M Szychowski; Alan T N Tita; Akila Subramaniam Journal: Obstet Gynecol Date: 2022-05-02 Impact factor: 7.623
Authors: L C Poon; H Yang; S Dumont; J C S Lee; J A Copel; L Danneels; A Wright; F Da Silva Costa; T Y Leung; Y Zhang; D Chen; F Prefumo Journal: Ultrasound Obstet Gynecol Date: 2020-06 Impact factor: 7.299
Authors: Nikita P Joshi; Aditi R Mane; Akriti S Sahay; Deepali P Sundrani; Sadhana R Joshi; Chittaranjan S Yajnik Journal: Reprod Sci Date: 2021-08-02 Impact factor: 2.924